B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening

被引:166
作者
D'Souza, SP
Yellon, DM
Martin, C
Schulz, R
Heusch, G
Onody, A
Ferdinandy, P
Baxter, GF
机构
[1] Univ London, Univ London Royal Vet Coll, Dept Basic Sci, London NW1 0TU, England
[2] UCL Hosp & Med Sch, Hatter Inst, London WC1E 6BT, England
[3] Univ Essen Gesamthsch Klinikum, Inst Pathophysiol, D-45122 Essen, Germany
[4] Univ Szeged, Dept Biochem, H-6720 Szeged, Hungary
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2003年 / 284卷 / 05期
关键词
cGMP; ischemia-reperfusion; infarct size; preconditioning;
D O I
10.1152/ajpheart.00902.2002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
B-type natriuretic peptide (BNP) has been reported to be released from the myocardium during ischemia. We hypothesized that BNP mediates cardioprotection during ischemia-reperfusion and examined whether exogenous BNP limits myocardial infarction and the potential role of ATP-sensitive potassium (K(ATP)) channel opening. Langendorff-perfused rat hearts underwent 35 min of left coronary artery occlusion and 120 min of reperfusion. The control infarct-to-risk ratio was 44.8 +/- 4.4% (means +/- SE). BNP perfused 10 min before ischemia limited infarct size in a concentration-dependent manner, with maximal protection observed at 10(-8) M ( infarct-to-risk ratio: 20.1 +/- 5.2%, P < 0.01 vs. control), associated with a 2.5-fold elevation of myocardial cGMP above the control value. To examine the role of K(ATP) channel opening, glibenclamide (10(-6) M), 5-hydroxydecanoate (5-HD; 10(-4) M), or HMR-1098 (10(-5) M) was coperfused with BNP (10(-8) M). Protection afforded by BNP was abolished by glibenclamide or 5-HD but not by HMR-1098, suggesting the involvement of putative mitochondrial but not sarcolemmal K(ATP) channel opening. We conclude that natriuretic peptide/cGMP/K(ATP) channel signaling may constitute an important injury-limiting mechanism in myocardium.
引用
收藏
页码:H1592 / H1600
页数:9
相关论文
共 40 条
[1]   Role of bradykinin in preconditioning and protection of the ischaemic myocardium [J].
Baxter, GF ;
Ebrahim, Z .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (04) :843-854
[2]   Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use [J].
Boomsma, F ;
van den Meiracker, AH .
CARDIOVASCULAR RESEARCH, 2001, 51 (03) :442-449
[3]   Endothelial NO/cGMP system contributes to natriuretic peptide-mediated coronary and peripheral vasodilation [J].
Brunner, F ;
Wölkart, G .
MICROVASCULAR RESEARCH, 2001, 61 (01) :102-110
[4]  
CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.biochem.60.1.553
[5]   Lack of correlation between myocardial nitric oxide and cyclic guanosine monophosphate content in both nitrate-tolerant and -nontolerant rats [J].
Csont, T ;
Páli, T ;
Szilvássy, Z ;
Ferdinandy, P .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (09) :1139-1144
[6]   NATRIURETIC HORMONES [J].
ESPINER, EA ;
RICHARDS, AM ;
YANDLE, TG ;
NICHOLLS, MG .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1995, 24 (03) :481-&
[7]   K-ATP channel modulation in working rat hearts with coronary occlusion: Effects of cromakalim, cicletanine, and glibenclamide [J].
Ferdinandy, P ;
Szilvassy, Z ;
DroyLefaix, MT ;
Tarrade, T ;
Koltai, M .
CARDIOVASCULAR RESEARCH, 1995, 30 (05) :781-787
[8]   Cardioselectivity of the sulphonylurea HMR 1098:: studies on native and recombinant cardiac and pancreatic KATP channels [J].
Fox, JEM ;
Kanji, HD ;
French, RJ ;
Light, PE .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (02) :480-488
[9]   ATP-SENSITIVE POTASSIUM CHANNELS AND MYOCARDIAL PRECONDITIONING [J].
GROSS, GJ .
BASIC RESEARCH IN CARDIOLOGY, 1995, 90 (02) :85-88
[10]   PROTECTIVE EFFECTS OF ATP-SENSITIVE POTASSIUM CHANNEL OPENERS IN MODELS OF MYOCARDIAL-ISCHEMIA [J].
GROVER, GJ .
CARDIOVASCULAR RESEARCH, 1994, 28 (06) :778-782